Ocular Therapeutix (OCUL) Financials: History & Chart

Ocular Therapeutix, Inc.(OCUL)

Biotechnology · Bedford, MA

$7.35+0.10 (+1.35%)

Delayed quote: Oct 6, 2026, 1:20 PM EDT

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Bedford, MA

325 employees

www.ocutx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pravin U. Dugel

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	52.05M	13.47M	10.79M	13.25M	14.54M	13.46M	10.70M	17.08M	15.43M
Cost of Goods Sold	6.71M	2.01M	1.33M	1.59M	1.77M	1.94M	1.26M	1.23M	1.56M
Gross Profit	45.35M	11.46M	9.46M	11.66M	12.77M	11.52M	9.44M	15.85M	13.86M
Gross Profit Margin	87.1%	85.1%	87.7%	88.0%	87.8%	85.6%	88.2%	92.8%	89.9%
Total Operating Expenses	359.25M	93.57M	102.80M	81.42M	81.47M	79.16M	73.35M	66.43M	59.86M
Research & Development	223.51M	54.14M	66.21M	50.80M	52.36M	51.08M	42.86M	40.99M	37.05M
Selling, General & Administrative	135.74M	39.44M	36.58M	30.62M	29.11M	28.07M	30.50M	25.44M	22.81M
Operating Income (EBIT)	-313.91M	-82.11M	-93.34M	-69.76M	-68.70M	-67.64M	-63.92M	-50.58M	-46.00M
Operating Margin	-603.0%	-609.3%	-865.5%	-526.5%	-472.3%	-502.6%	-597.5%	-296.1%	-298.2%
Income Before Tax (EBT)	-301.45M	-78.76M	-88.61M	-64.65M	-69.42M	-67.81M	-64.05M	-48.39M	-36.49M
Interest Income	22.57M	5.45M	6.05M	7.34M	3.73M	3.46M	3.83M	4.67M	5.65M
Interest Expense	11.40M	2.79M	2.78M	2.83M	3.00M	3.02M	2.98M	3.11M	3.22M
Other Income/Expense	12.46M	3.35M	4.73M	5.11M	-720K	-173K	-136K	2.19M	9.51M
Net Income	-301.45M	-78.76M	-88.61M	-64.65M	-69.42M	-67.81M	-64.05M	-48.39M	-36.49M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-579.1%	-584.5%	-821.6%	-488.0%	-477.3%	-503.9%	-598.7%	-283.3%	-236.6%
EBITDA	-308.45M	-80.26M	-92.06M	-68.51M	-67.63M	-66.61M	-62.94M	-49.63M	-45.04M
EBITDA Margin	-592.6%	-595.6%	-853.6%	-517.1%	-465.0%	-494.9%	-588.3%	-290.5%	-292.0%
Depreciation & Amortization	5.45M	1.85M	1.28M	1.25M	1.07M	1.03M	981K	951K	959K
EPS Basic	-1.42	-0.35	-0.40	-0.29	-0.38	-0.39	-0.38	-0.29	-0.22
EPS Diluted	-1.42	-0.35	-0.40	-0.29	-0.38	-0.39	-0.38	-0.29	-0.22
Weighted Average Basic Shares	224.95M	224.95M	224.10M	222.92M	183.92M	172.59M	169.40M	168.02M	166.99M
Weighted Average Diluted Shares	224.95M	224.95M	224.10M	222.92M	183.92M	172.59M	169.40M	168.02M	166.99M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	51.82M	63.72M	58.44M	51.49M	43.52M	17.40M	4.23M	1.99M
Cost of Goods Sold	6.57M	5.63M	5.28M	4.54M	4.41M	2.08M	2.33M	465K
Gross Profit	45.25M	58.10M	53.16M	46.95M	39.12M	15.32M	1.90M	1.52M
Gross Profit Margin	87.3%	91.2%	91.0%	91.2%	89.9%	88.0%	45.0%	76.6%
Total Operating Expenses	315.39M	229.88M	135.54M	125.61M	117.15M	78.17M	87.70M	60.64M
Research & Development	197.10M	127.64M	61.05M	53.46M	50.08M	28.69M	41.09M	36.91M
Selling, General & Administrative	118.30M	102.24M	74.49M	72.15M	67.07M	49.47M	46.61M	23.73M
Operating Income (EBIT)	-270.02M	-171.78M	-82.38M	-78.65M	-78.04M	-62.85M	-85.80M	-59.12M
Operating Margin	-521.0%	-269.6%	-141.0%	-152.7%	-179.3%	-361.1%	-2029.9%	-2970.8%
Income Before Tax (EBT)	-265.94M	-193.51M	-80.74M	-71.04M	-6.55M	-155.64M	-86.37M	-59.98M
Interest Income	18.36M	20.28M	3.98M	798K	33K	168K	1.23M	879K
Interest Expense	11.84M	13.58M	11.34M	7.02M	6.67M	6.77M	6.10M	1.74M
Other Income/Expense	4.08M	-21.73M	1.65M	7.62M	71.48M	-92.79M	-570K	-860K
Net Income	-265.94M	-193.51M	-80.74M	-71.04M	-6.55M	-155.64M	-86.37M	-57.69M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.29M
Net Profit Margin	-513.2%	-303.7%	-138.1%	-138.0%	-15.1%	-894.3%	-2043.3%	-2899.1%
EBITDA	-265.69M	-168.00M	-79.40M	-76.55M	-75.62M	-60.07M	-83.27M	-56.83M
EBITDA Margin	-512.7%	-263.6%	-135.9%	-148.6%	-173.7%	-345.2%	-1970.0%	-2855.9%
Depreciation & Amortization	4.32M	3.79M	2.98M	2.11M	2.42M	2.77M	2.53M	2.29M
EPS Basic	-1.42	-1.22	-1.09	-1.04	-1.05	-2.56	-1.91	-1.57
EPS Diluted	-1.42	-1.22	-1.02	-0.97	-0.98	-2.56	-1.91	-1.57
Weighted Average Basic Shares	187.24M	158.26M	79.83M	76.88M	76.39M	60.75M	45.27M	38.12M
Weighted Average Diluted Shares	187.24M	158.26M	85.60M	82.64M	82.16M	60.75M	45.27M	38.12M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.